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AbstrACt
Objective To investigate UK healthcare professionals’ 
perceptions and perspectives towards biosimilar 
infliximab, etanercept and insulin glargine and the 
potential barriers and facilitators to their prescribing.
Design A cross-sectional qualitative study design was 
used.
setting Five hospitals within the West Midlands area in 
UK.
Interventions 30 min face-to-face, semistructured 
interviews of healthcare professionals.
Participants 22 healthcare professionals (consultants, 
nurses and pharmacists) participated in the semistructured 
interviews.
Outcomes Participants’ opinion and attitudes about 
biosimilars and the barriers and facilitators to the 
prescribing of infliximab, etanercept and insulin glargine 
biosimilars in gastroenterology, rheumatology and 
diabetology specialties.
results This study showed that UK healthcare 
professionals had good knowledge of biosimilars and 
were content to initiate them. Healthcare professionals 
disagreed with biosimilar auto-substitution at pharmacy 
level and multiple switching. Subtle differences among 
healthcare professionals were identified in the acceptance 
of switching stable patients, indication extrapolation and 
cost savings sharing.
Conclusion Safety and efficacy concerns, patients’ 
opinion and how cost savings were shared were the 
identified barriers to considering prescribing biosimilars. 
Real-life data and financial incentives were the suggested 
facilitators to increase biosimilar utilisation.
IntrODuCtIOn 
Biosimilars are an alternative to expen-
sive branded biological regimens. Finan-
cial pressures on healthcare systems means 
increasing the use of biosimilars is becoming 
more important. As a result, major guid-
ance documents in oncology, haematology, 
gastroenterology and rheumatology have 
incorporated biosimilars into recommended 
treatment regimens.1 Professional associa-
tions and societies have also supported the 
utilisation of biosimilars but to a different 
extent. The rate of uptake of biosimilars has 
been keenly debated among the stakeholders 
in different specialties.2–4 Healthcare profes-
sionals (HCPs) have been surveyed on their 
knowledge, attitude and practice towards 
biosimilars in the UK.5 The results of that 
survey showed a good understanding and 
awareness of UK HCPs of biosimilars with a 
significant variation in attitude. This differ-
ence was reflected in their uptake of the 
corresponding biosimilars.
A survey of the literature revealed many 
surveys about HCPs’ knowledge, attitude and 
experience towards biosimilars,6–17 but only 
one in-depth study investigating the barriers 
to uptake.18 This study was undertaken in 
strengths and limitations of this study
 ► This study draws a variety of in-depth accounts from 
participants of different profession in different spe-
cialties to reveal the facilitators and barriers to the 
use of biosimilars in UK hospitals.
 ► We use the well-established framework method of 
qualitative analysis, which allows for comparisons 
to be made across cases and themes.
 ► Our approach shows the opinions of those prescrib-
ing biosimilars who accepted to take part in the 
study. This may not be a truly representative sample 
as it may not include those who were not using bio-
similars and/or those healthcare professionals more 
reluctant to prescribe who may not have received 
formal training about fundamental of biosimilars.
 ► While participants represented a variety of profes-
sional roles and range of perspectives, they were all 
recruited from West Midland’s hospitals in England 
and might therefore not be representative and gen-
eralisable across the whole of the UK.
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non-UK setting. Thus, the main aim of this study was to 
investigate in more detail the barriers and facilitators to 
the use of biosimilars by UK HCPs.
MethODs
A qualitative research method using face-to-face semi-
structured interviews was used to elucidate in-depth 
interviewee’s knowledge, perceptions and attitudes to 
biosimilars. A purposive convenience sampling of HCPs 
within the West Midlands hospitals with expertise in the 
clinical specialties of diabetes mellitus, ulcerative colitis, 
Crohn’s disease, rheumatoid arthritis, ankylosing spondy-
litis and psoriatic arthritis where insulin glargine, inflix-
imab and etanercept were prescribed was used. These 
included prescribing HCPs in different professions and 
specialties in secondary care settings (consultants, prac-
tice nurses, nurse prescribers and independent prescriber 
pharmacists). In the UK, pharmacists and nurses can 
undertake further training to become registered indepen-
dent non-medical prescribers. Independent non-medical 
prescribers can legally prescribe any medicine within 
their sphere of competence which includes biologics.19
As part of the National Health Service (NHS) research 
approval process, an application was made via the NHS 
Health Research Authority to all 14 acute hospitals in the 
West Midlands. The research and development depart-
ments of seven of these sites (50%) gave approval for the 
research to be conducted in their hospitals. Stakeholders 
from these seven hospitals were invited by electronic mail 
and/or telephone to a single 30 min interview during the 
period of June–November 2017. A snowballing technique 
was used with the interviewees who positively replied to 
the invitation being asked to name further professionals 
within the specialty, who prescribed biologics/biosimilars. 
HCPs’ interviews took place at their offices. No incentives 
were offered to the participants who participated volun-
tarily. Specialty-specific semistructured interview guides 
were non-leading and non-judgemental and had been 
developed from an interpretation of the literature and a 
pilot with a small number of healthcare professionals and 
academics, and amended according to their comments 
and suggestions. The interview guides were designed to 
explore HCPs’ knowledge and attitude towards biosimi-
lars, prescribing practice of biosimilars in each specialty, 
the barriers to use of biosimilars and potential approaches 
to overcome these barriers. The interview guides were 
also informed by a review of the literature.
Before the interviews were conducted, the interviewees 
received a participant invitation letter, participant infor-
mation sheets and consent forms. Written and verbal 
informed consents were obtained from all participants 
(before starting the study) who were assured of data 
confidentiality and their right to withdraw at any time. 
The interview schedule began with a brief statement in 
the form of summary points about the research objec-
tives, why the research is being conducted and an over-
view of the questionnaires.
Semistructured interviews were conducted by MIA, a 
man, trained clinical pharmacist, PhD student. The inter-
views were digitally audio-recorded. Anonymised audio 
records were transcribed by an independent company. 
Transcripts were checked for accuracy following the tran-
scribing. Data were analysed using thematic analysis by 
MIA.20 The analysis consisted of six stages: familiarisa-
tion with the data, generating initial codes, searching for 
themes, reviewing themes, defining and naming themes 
and producing the report. The interviews were analysed 
using NVivo 11 Pro to facilitate the analysis. The study was 
approved.
Patient and public involvement
No patients or members of the public were involved in this 
study, but the questions were influenced by the results of 
the authors’ previously published patients’ web survey.21
results
Out of 99 recipients of invitation letters, 26 potential 
participants responded. Four participants withdrew 
before the interview day due to lack of time. A total of 22 
semistructured interviews were conducted in person with 
the HCPs from five hospital trusts (the University Hospital 
of North Midlands NHS Trust, the Staffordshire and 
Stoke on Trent Partnership NHS Trust, the Royal Wolver-
hampton NHS Trust, the Heart of England NHS Trust 
and the University Hospitals Coventry and Warwickshire 
NHS Trust). Data saturation was achieved. Table 1 shows 
the demographic characteristics of interview participants.
Major themes
Five main themes emerged from the semistructured 
interviews with HCPs: perception of biosimilars, atti-
tude towards biosimilar prescribing, HCPs’ views on the 
evidence base for biosimilars, facilitators to prescribing 
biosimilars and barriers to prescribing biosimilars.
Perception of biosimilars
All interviewed HCPs expressed an understanding of 
the concept of biosimilars. They believed that a biosim-
ilar is a copy of the reference biological medicine. HCPs 
attributed the difference between biosimilars and generic 
medicines to the biological nature of biosimilars versus 
the chemical nature of generics, the difference in manu-
facturing processes and structure.
‘They are, [biosimilars] on a parallel to generics, for 
other drugs but because they’re biologically active 
substances, they obviously have to be a lot more care 
when they were developed…’ (G5)
The main sources of ‘first knowledge’ of biosimilars 
were conferences, pharmaceutical industry representa-
tives, scientific journals and colleagues.
Attitude towards biosimilar prescribing
The majority of HCPs were content to initiate biosimilars. 
A minority of rheumatology HCPs and diabetology HCPs 
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felt that they were under pressure from their organisa-
tion to initiate new patients on biosimilars. They felt they 
had limited options for giving new patients the choice 
between biosimilars and reference biological medicine.
‘We’ve been forced in a way to put all our new pa-
tients onto a biosimilar.’ (R2)
All gastroenterology HCPs and a minority of rheu-
matology HCPs were content to switch patients from 
a reference biological medicine to a biosimilar. For 
gastroenterologists, the availability of appropriate data, 
guidance from their professional associations and the 
experiences of colleagues in other trusts influenced their 
decision of whether or not to switch to a biosimilar.
Two rheumatology HCPs expressed the view that they 
were happier with initiation rather than switching. This 
view was based on concerns about disrupting the care of 
stable patients for purely economic reasons.
‘Actually, I’m happier to initiate new patients than I 
am a switch. At a patient level, I think it’s really tricky 
if you’ve got a really good response to an agent and 
we’re asking people to switch for purely economic 
considerations.’ (R1)
The majority of diabetology HCPs were reluctant to 
switch patients from the reference biological medicine to 
a biosimilar for cost reasons. They felt a switch requires 
long-term monitoring of patients and they are dealing 
with complicated cases for just a short period of time. 
Also, as the hospitals were not paying for insulin after the 
patient’s discharge, they felt any switching process should 
be done by general practitioners in primary care settings 
as it would be the primary care budget that would benefit.
‘I think that it would require close monitoring to 
switch your patients because as I say they don’t pro-
duce exactly the same results’ … ‘the hospital setting 
is not the most appropriate place to switch in terms 
of if we switch a patient and then we discharge them 
home there is going to need to be close follow.’ (D1)
All HCPs who were comfortable with switching 
expressed the view that patients should be given the choice 
between biosimilars and reference biological medicine 
when switching. HCPs outlined two switching strategies, 
either an additional consultation, explaining the reasons 
for switching and the possibility of switching back to their 
reference agent, or sending out letters informing patients 
of the proposed switch.
‘The gastroenterology consultants were happy for the 
patients to receive a letter and the emphasis was tell 
us if you don’t like what we've told you otherwise you 
Table 1 Demographic characteristics of the participants
Code Gender Profession Specialty Age
Years of 
experience
G1 Female Pharmacist Gastroenterology 44 17
G2 Female Nurse Gastroenterology 41 3
G3 Male Pharmacist Gastroenterology 51 15
G4 Female Nurse Gastroenterology 37 2
G5 Female Consultant Gastroenterology 59 22
G6 Female Pharmacist Gastroenterology 36 5
G7 Male Consultant Gastroenterology 61 25
R1 Female Consultant Rheumatology 49 9
R2 Male Consultant Rheumatology 67 20
R3 Female Nurse Rheumatology 40 10
R4 Female Nurse Rheumatology 59 15
R5 Female Consultant Rheumatology 54 14
R6 Male Consultant Rheumatology 64 24
R7 Male Consultant Rheumatology 49 10
D1 Female Pharmacist Diabetes 38 3
D2 Male Consultant Diabetes 52 14
D3 Female Nurse Diabetes 61 20
D4 Male Nurse Diabetes 64 21
D5 Female Nurse Diabetes 64 22
D6 Male Consultant Diabetes 54 11
D7 Male Consultant Diabetes 55 15
D8 Male Consultant Diabetes 48 12
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will automatically be switched next time you come 
in.’ (G6)
‘The rheumatology consultant wanted a very more 
sort of touchy-feely approach with his patients, he 
didn’t want to lose their confidence and he very 
much wanted a personal clinic face-to-face appoint-
ment to talk about the switch and this is quite inter-
esting.’ (R5)
The majority of HCPs appeared to have a negative 
opinion and/or attitude towards the automatic substitu-
tion of the reference biological medicine with a biosim-
ilar at the pharmacy level. A minority of HCPs believed 
that automatic substitution would be accepted in the next 
few years.
‘Not currently, I think it will probably be the situation 
in five years’ time when everybody has used them for 
a period of time and has the confidence in the inter-
changeability.’ (G6)
About 50% of gastroenterology HCPs and rheuma-
tology HCPs indicated that any cost savings should 
be shared between their department and the Clinical 
Commissioning Groups (CCG). Those HCPs believed 
that this ‘gain share’ would expand the services provided 
to the patients.
‘I think these savings will come to the department be-
cause we’ve already negotiated that it’ll fund an extra 
nurse. The patient will also get the benefit.’ (R4)
In contrast, the remaining gastroenterology HCPs and 
rheumatology HCPs believed that cost savings would be 
for the CCGs. Those HCPs where there was no ‘gain 
sharing’ believed that biosimilars had a negative impact 
on their department due to increased workload associ-
ated with switching patients (including calling, sending 
letters and extra consultation).
‘At the moment, with no gain sharing, it has a nega-
tive cost implication in that we’re having to get peo-
ple up who are switching.’ (R1)
The majority of rheumatology and diabetology HCPs 
agreed that if the price of the reference biological agent 
became equivalent to the price of biosimilars, they would 
choose to prescribe the reference.
‘Abasaglar® has only got validity if it’s cheaper. If you 
had the same price, what’s the use of having biosim-
ilars which are similarly priced? If Lantus® price be-
comes similar to Abasaglar®, I would never prescribe 
Abasaglar®.’ (D6)
HCPs views on evidence base on biosimilars
Gastroenterology HCPs expressed more confidence 
and/or fewer concerns than other specialists. They indi-
cated that indication extrapolation was the main source 
of hesitance about biosimilar uptake, but this had been 
overcome.
‘Indication extrapolation was the main reason that 
the British Society Gastroenterology were hesitant 
and the main reason why our clinicians were hesitant 
in gastroenterology, they requested to see trials in 
gastro patients before.’ (G6)
Gastroenterology HCPs also suggested that adalimumab 
biosimilar uptake would be easier than infliximab biosim-
ilars even if the indications were extrapolated from other 
specialties because of prior experience with infliximab.
‘For adalimumab biosimilar, If the finances are 
agreed up front it will probably go ‘wow’. I think 
because gastro made the move with Inflectra® they 
won’t be hesitant with the adalimumab in the same 
way as they were because the concept has already 
been tried.’ (G6)
By contrast, the majority of rheumatology HCPs had 
concerns about indication extrapolations. Rheumatology 
HCPs considered their patients were very sensitive with 
higher multimorbid risks than patients with ulcerative 
colitis. In some cases, they openly declared themselves to 
be more mistrustful of biosimilars than other specialists.
‘Well I’d be very, very wary and I know there is an-
other example isn’t there of one of the existing bio-
logics of extrapolation of infliximab, that’s right yes, 
but I would be wary about accepting gastroenterolo-
gy experience and extrapolating to rheumatoid pa-
tients’… ‘We are very obsessive!! Very mistrustful and 
obsessive!!’ (R7)
The majority of HCPs in all specialties felt multiple 
switching between a reference biologic and a biosimilar 
on the basis of cost alone to be irrational, with the poten-
tial for reducing the trust between patient and clinician. 
HCPs also expressed their preference to keep the patient 
on the biosimilar if the patient has no problems.
They were prepared to switch from biosimilars back 
to the reference biologic if they had efficacy or safety 
concerns.
‘I would imagine with the workload that’s gone into 
the switch between Remicade® and Inflectra® unless 
there was a significant cost saving I doubt that we 
would switch again because of the implications and 
the workload that it increased when we had to do it. I 
just don’t think they’d like the instability of constant-
ly switching drugs.’ (G2)
‘Even if they dropped their price to the equivalent 
or near the price of the biosimilar, we wouldn’t go 
back.’ (G3)
‘I think that multiple switching is irrational because 
there’s such a paperwork chase to change prescrip-
tion that we wouldn’t probably do that.’ (R6)
Facilitator to prescribing biosimilars
Gastroenterology HCPs believed that the guidance from 
the British Society of Gastroenterology and the National 
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Institute for Health and Care Excellence (NICE), expe-
rience from other trusts and the national registry are 
enough for using biosimilars. Others believed that they 
have switched almost all patients (with the exception of 
the reluctant patients or those with contraindications). 
Diabetologists thought that the number of patients using 
biosimilars would increase naturally.
‘To use infliximab biosimilars, I think the data is there 
now to be honest with you, like I said the BSG have is-
sued a guidance, NICE have issued a guidance, there 
have been quite a few Trusts throughout the UK who 
have done the switch, so I think the evidence is there 
and we are happy to switch to infliximab.’ (G3)
‘I don't think we need anything. I think it is increas-
ing so we’re seeing more patients, more patients are 
requiring basal insulin’ … ‘I think naturally the pre-
scription rates are increasing.’ (D5)
In contrast, half of diabetology, rheumatology and 
some gastroenterology HCPs valued the availability of 
more supportive evidence on the efficacy and safety of 
biosimilars from other Trusts.
‘Other trusts’ experiences possibly influence my 
views. Because the trial data is very clinical and it’s 
often when the drugs come out into real-life clinical 
situations that you get actual useful data.’ (D3)
Determining who benefited from the cost savings was 
the main reason for the delay in including biosimilars in 
hospital formulary and their use. Some HCPs suggested 
that offering cost sharing with the department would 
influence their use of biosimilars.
‘Biggest delay to introducing biosimilars into the 
Trust and into other Trusts as well have been political 
arguments over the savings and who is going to get 
them.’ (G6)
‘If they offer us a gain-share, then this would defi-
nitely influence the use.’ (D4)
Barriers to prescribing biosimilars
The majority of HCPs indicated that the development of 
an unexpected adverse effect or the increase in the rate 
of side effects among patients locally or nationwide would 
inhibit them from prescribing biosimilars.
‘If the patients did set against it; if you saw lots of bad 
side-effects; if it wasn’t working with the client group 
for some reason. If you had more people not getting 
the benefit, then you wouldn’t want to carry on.’ (R3)
A minority of HCPs in different specialties believed that 
if a patient had a strong opinion against biosimilars, they 
would not switch them.
‘If patients really didn’t want to do it because you do 
have to explain to a patient when you give it the bio-
similar and if they didn’t want to use it that's totally 
up to them and it rules it out completely because a 
patient has the choice at the end of the day.’ (D1)
The majority of rheumatology HCPs mentioned the 
administration device of biological medicine as an impor-
tant factor or barrier to prescribing. Complicated, unsuit-
able and non-user-friendly devices were the main causes 
of errors and reluctance by patients. A rheumatology 
HCP also outlined that some patients were not switched 
from the reference etanercept (Enbrel) to the biosimilar 
(Benepali) either due to the unavailability of all dosage 
strengths of Benepali or being allergic to the preservative 
available in the pens.
‘We can’t switch all patients because Benepali® don’t 
do a 25 mg syringe and they also don’t do the 25 mg 
vial  without the preservatives. Because we’ve got some 
patients allergic to the preservative and so they’re on 
the vials.’ (R4)
Interestingly, the majority of rheumatology HCPs 
believed that Benepali injecting pen was better than 
Enbrel’s pen due to its ease of use, fewer steps for dosage 
administration and being less painful. These factors lead 
to some patient on Enbrel requesting Benepali.
“A lot of the patients are finding the Benepali® pen a 
lot easier because they just push it down, so they ha-
ven’t gotten to use their thumb to press the button.’ 
(R3)
The majority of diabetology HCPs were familiar with 
insulin glargine administration devices and believed that 
the biosimilar (Abasaglar) pen device (Kwick pen) is very 
similar to the reference (Lantus) pen device (SoloSTAR 
pen).
DIsCussIOn
The findings of the study indicated that the majority of 
HCPs in all specialties shared some similarity in knowl-
edge, opinions and attitudes on biosimilar prescribing 
practice. These similarities included: their good level of 
knowledge, contentment (happiness) to initiate newly 
diagnosed patient on biosimilars without giving patient 
the choice, disagreement with automatic substitution of 
biosimilars at the pharmacy level and disagreement with 
multiple switching for cost reasons. They differed on their 
acceptance of switching to biosimilars, the pathway of 
switching and how to inform the patient about switching, 
acceptance of indication extrapolation and cost saving 
and sharing. The findings from this study also revealed 
that real-world data about safety and efficacy and finan-
cial aspects of the Trust had the potential to optimise 
biosimilar utilisation.
This study has both strengths and limitations. It is 
the first in-depth study investigating the facilitators and 
barriers of biosimilar prescribing among UK specialty 
HCPs. It is potentially limited by the inclusion criteria for 
the semistructured interviews which might have resulted 
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in participating specialty HCPs in gastroenterology, rheu-
matology and diabetology being skewed towards those 
who tend to be prescribing biosimilars. This might have 
resulted in participants being primarily early adopters of 
new therapies, with different perceptions of biosimilars to 
HCPs not currently prescribing biosimilars. Furthermore, 
it is highly likely that those who accepted the interview are 
already engaged in the use of biosimilars and ‘aligned’ 
with the questions raised. Due to the small sample size 
and the diversity of specialties and organisational back-
ground, it was not possible to identify a difference in atti-
tude associated with demographics.
Like this study, several other studies have shown HCPs 
had a good understanding of the concept of biosimilars, 
used similar sources of information about biosimilars 
(eg, conferences, online information, medical represen-
tatives, industry, scientific journal, professional bodies 
guidelines and colleagues),5 9 22 were more prepared to 
initiate than to switch patients to and were concerned 
or uncomfortable with a pharmacist auto-substituting a 
patient’s biological medicine.7 10 13 22
The main areas of differences in views and attitudes 
between HCPs of different specialties were acceptance 
of switching to biosimilars, data and indication extrapo-
lation from brand (reference) biologics and attitudes to 
cost savings and sharing those savings.
Gastroenterology HCPs were more open to switching 
established patients to biosimilars than rheumatology and 
diabetology HCPs, explaining that the availability of data 
supporting switching, guidance from professional bodies 
and associations and experience from other Trusts and 
countries encouraged them to switch patients. Rheuma-
tology HCPs were happier to initiate patients on a biosim-
ilar rather than to switch, possibly due to them using less 
infliximab than their gastroenterology colleagues, and 
the fact that the molecule they used more frequently, 
etanercept, only recently became available as a biosim-
ilar (March 2016). In contrast to gastroenterologists, 
they wanted more real-life data on switching and a clear 
pathway for switching to overcome their concerns about 
biosimilars; the lack of guidance from their professional 
association may also have had some influence.
Diabetology HCPs were reluctant to switch to a biosim-
ilar for cost reasons, primarily because they dealt in the 
short term with complicated patients in the hospitals 
then; once controlled, they discharge them to primary 
care. Thus, as the hospitals are only paying for the insulin 
in the short term and not for the total duration of treat-
ment, the diabetologists felt that general practitioners 
should do the switching as they have both the capability 
to monitor patients and it would be their budget that 
benefited. This links to the attitude of some other HCPs 
who were only prepared to switch if the savings directly 
benefited their department. This reflects results from 
previous studies by Chapman et al, Hemmington et al and 
O’Callaghan et al.5 22 23
In terms of the pathway and how best to inform patients 
about potential switches, gastroenterologists were satisfied 
with indirect contact, simply informing the patient by 
post, whereas rheumatology preferred face-to-face consul-
tations, believing that this gave them a chance to relieve 
any patient concerns. This reflects the National Rheuma-
toid Arthritis Society position that switching patient to 
biosimilars can be alarming for patients unless there is 
clear discussion and agreement between the consultant/
prescriber and the patient with both risks and benefits 
explored and explained.24
The difference between the positions of specialties on 
switching could be attributed to the difference in the 
settings, administration device and method of adminis-
tration of the biologic. Gastroenterology HCPs frequently 
used infliximab, administered to inpatients as an intra-
venous infusion for both the brand (reference) biologic 
and the biosimilar; patients may not experience any 
significant difference as there is no change in mode of 
administration. By contrast, rheumatology HCPs mainly 
used etanercept and relatively little infliximab. Etaner-
cept is used in the outpatient or home setting, self-admin-
istered and marketed in different administration devices; 
thus, the patient would notice the difference in the shape 
of the device and the mechanism (steps) of self-admin-
istration and there are more likely to be concerns to be 
addressed by the treating HCPs. Results from the study 
by Chapman et al showed that the less complicated, user-
friendly with less number of steps for preparation of the 
dose were the most acceptable administration devices.25 
The unavailability of similar dosage form or strength was 
responsible for some patients not being switched from 
Enbrel to Benepali. The good design and ease of use of 
the administration device of Benepali led some patients 
to request to be switched to the biosimilar. This result 
was in line with Thakur et al’s study results which showed 
that France, Germany, Italy, Spain and UK rheumatology 
nurses and rheumatoid arthritis patients would prefer 
Benepali autoinjector, as it is easier to operate and more 
intuitive to use compared with Enbrel MyClic autoin-
jector.26 27
Diabetology HCPs were less concerned about the 
administration device of insulin glargine biosimilar 
(Abasaglar), as Abasaglar was launched in Lilly devices 
which were already in use as the prefilled Kwik pen and 
the reusable Savvio pen. These devices are similar to 
Lantus administration devices, prefilled and reusable 
SoloSTAR pens.28 Wilkins et al’s study results showed 
only 1.5% of surveyed patients with diabetes would be 
concerned about the design administration device if they 
were offered biosimilar insulin glargine.29 Diabetology 
HCPs expressed the view that patients with diabetes had 
the concept and the technique of insulin administration 
devices and only slight differences existed between these 
devices. This result was in line with New Zealand Phar-
maceutical Management Agency that switching from 
Lantus to Abasaglar would not necessarily be problem-
atic for patients with diabetes as there is a precedent for 
switching between brands of insulin and these are essen-
tially biosimilars.30
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Despite the fact that biosimilar indication extrapola-
tion has been a source of hesitancy and debate among 
HCPs,31 gastroenterology HCPs expressed that their 
experience with indication extrapolation of infliximab 
biosimilars from rheumatology to gastroenterology was 
successful. They suggested that, given this positive expe-
rience, they were now more positive and open towards 
the concept of indication extrapolation, which could 
lead to a fast uptake of upcoming adalimumab biosimi-
lars. Danese et al’s study showed that 25% of European 
gastroenterologists were concerned about indication 
extrapolation.14 Rheumatology HCPs were less confident 
and dissatisfied with indication extrapolation from other 
specialties and believed that biosimilars should be tested 
for each indication. These HCPs thought that there are 
differences in mechanism of action, dose, frequency and 
the multimorbidity of the diseases when using a biologic 
such as infliximab in rheumatoid arthritis and Crohn’s 
disease. Grabowski et al’s study showed that only 32% 
of Canadian rheumatologists were confident in indica-
tion extrapolation.10 In a similar position, diabetology 
HCPs also expressed their dissatisfaction with indication 
extrapolation of the reference (Lantus) to the biosimilar 
(Abasaglar); some diabetology HCPs expressed that they 
had a bad experience with previous insulin biosimilars 
that have been withdrawn from the market such as Marvel 
Insulin.
HCPs whose department shared part of the savings 
with commissioners appeared content with using biosim-
ilars and believed that biosimilar utilisation would 
improve their department and the service provided to 
the patients; As these departments had invested shared 
savings to fund extra nurse (biological nurse) that would 
help the department and the patients.
In contrast, HCPs whose department had not received 
a share of the cost savings believed these savings would go 
to the CCG. This latter group felt biosimilar utilisation 
had a negative impact on their department, department 
resources and to the service provided to the patients 
because the switching process meant HCPs were running 
extra clinics and meeting with patients more frequently, 
with monitoring and more associated paperwork. This is 
similar to Regional Medicines Optimisation Committees 
discussion summary in 2017 that stated increased work-
load for biosimilar switching is one of the challenges 
facing switching in a department and there may be lack 
of additional staffing to handle it.32 HCPs also weighted 
cost savings and sharing as important factors influencing 
biosimilar use; the more cost saving associated with a 
biosimilar, the more the chance of choosing this biosim-
ilar. A recent budget impact analysis in the UK estimated 
that the entry of new anti-TNFs (tumor necrosis factors) 
would result in a cumulative savings of £285 million by 
2020.33 Hospitals and department negotiations with 
commissioners about ‘gain share’ could either enhance 
or delay the uptake of biosimilars. If gain share was 
possible this would incentivise HCPs to use these biosimi-
lars if they were offered to the department. By contrast, if 
they were not offered a share of savings, biosimilars would 
be considered to have a negative impact on their depart-
ments and utilise department’s resources.
Several barriers to biosimilar utilisation were identified 
in this study. Safety and efficacy concerns were the most 
commonly raised barriers that might prevent HCPs from 
considering prescribing biosimilars. The lack of long-
term safety data of biosimilars and the complex nature 
of the protein raised HCPs’ concerns about unexpected 
adverse events, increasing the incidence of serious side 
effect or increased development of infections. This result 
was in line with the study result of Dylst et al, Narayanan 
and Nag, Chapman et al and O’Callaghan et al.5 15 18 22
Patient’s opinions and reluctance to accept biosimilars 
on the basis of cost alone was identified as a barrier to the 
uptake of biosimilars by some specialty HCPs. A patient 
on a reference biological medicine who has been offered 
to be switched to a biosimilar has the right to refuse to 
be switched even after a consultation with the treating 
HCPs. Consent should be taken from the patient before 
switching process takes place. Waller et al’s study showed 
that 56% of German rheumatoid patients reported by 
rheumatologists were unhappy to be switched to biosim-
ilars for non-clinical reasons.34 Similarly, Sullivan et 
al’s study showed that 43% of German gastroenterology 
patients reported by gastroenterologists were unhappy to 
be switched to biosimilars for non-clinical reasons.35
COnClusIOn
This study showed that UK HCPs had good understanding 
of biosimilars with subtle difference between specialties 
in their attitude to using biosimilars. Gastroenterology 
HCPs were more open and less concerned than rheuma-
tology and diabetologists towards biosimilar initiation and 
switching. Safety and efficacy concerns, patients’ opinion 
and how cost savings were shared were the identified 
barriers to considering prescribing biosimilars. Real-life 
data and financial incentives were the suggested facilita-
tors to increase biosimilar utilisation.
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